X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (411) 411
female (334) 334
male (244) 244
adult (183) 183
middle aged (180) 180
animals (170) 170
thyroiditis - chemically induced (149) 149
thyroiditis, autoimmune - chemically induced (149) 149
endocrinology & metabolism (126) 126
index medicus (112) 112
hypothyroidism - chemically induced (87) 87
aged (86) 86
thyroiditis (82) 82
hypothyroidism (81) 81
mice (74) 74
thyroiditis, autoimmune - immunology (74) 74
thyroid gland - drug effects (71) 71
rats (68) 68
disease (67) 67
interferon-alpha - adverse effects (65) 65
thyroid function tests (64) 64
therapy (59) 59
hyperthyroidism - chemically induced (58) 58
thyroid gland - pathology (58) 58
thyrotropin - blood (57) 57
thyroid gland - immunology (55) 55
medicine, general & internal (53) 53
adolescent (51) 51
thyrotoxicosis - chemically induced (51) 51
immunology (49) 49
thyroxine - blood (47) 47
antiviral agents - adverse effects (46) 46
autoantibodies - blood (44) 44
iodine - adverse effects (42) 42
thyroglobulin - immunology (42) 42
risk factors (41) 41
amiodarone - adverse effects (40) 40
autoimmunity (38) 38
hyperthyroidism (38) 38
autoimmune diseases - chemically induced (37) 37
thyroiditis - complications (37) 37
thyroid diseases (36) 36
thyroiditis - immunology (36) 36
thyroiditis, autoimmune - pathology (36) 36
autoantibodies (35) 35
thyrotoxicosis (35) 35
thyroid diseases - chemically induced (34) 34
thyroiditis, autoimmune - complications (34) 34
autoimmune thyroiditis (33) 33
autoimmune-thyroiditis (33) 33
endocrine system (33) 33
hepatitis c, chronic - drug therapy (33) 33
thyroglobulin (33) 33
disease models, animal (32) 32
thyroiditis - pathology (32) 32
time factors (32) 32
antineoplastic agents - adverse effects (31) 31
endocrine system diseases (31) 31
child (30) 30
mice, inbred nod (30) 30
iodine (29) 29
thyroid hormones - blood (29) 29
antibodies (28) 28
graves-disease (28) 28
thyroid gland (27) 27
thyroid gland - metabolism (27) 27
thyroiditis, autoimmune - drug therapy (27) 27
triiodothyronine - blood (27) 27
antibodies, monoclonal - adverse effects (26) 26
autoimmune diseases (25) 25
diagnosis, differential (25) 25
interferon-alpha - therapeutic use (25) 25
lymphocytic thyroiditis (25) 25
oncology (25) 25
recombinant proteins (25) 25
autoantibodies - immunology (24) 24
follow-up studies (24) 24
hypothyroidism - etiology (24) 24
iodine - administration & dosage (24) 24
pregnancy (24) 24
chronic viral-hepatitis (23) 23
dysfunction (23) 23
goiter - chemically induced (23) 23
hypothyroidism - drug therapy (23) 23
thyroid gland - physiopathology (23) 23
thyroiditis, autoimmune - diagnosis (23) 23
treatment outcome (23) 23
autoantibodies - analysis (22) 22
bipolar disorder - drug therapy (22) 22
cancer (22) 22
disorders (22) 22
prospective studies (22) 22
aged, 80 and over (21) 21
anti-arrhythmia agents - adverse effects (21) 21
antiviral agents - therapeutic use (21) 21
pharmacology & pharmacy (21) 21
thyroiditis - drug therapy (21) 21
graves disease - immunology (20) 20
medicine & public health (20) 20
prevalence (20) 20
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (485) 485
German (20) 20
French (12) 12
Spanish (9) 9
Polish (8) 8
Japanese (7) 7
Hungarian (3) 3
Chinese (2) 2
Norwegian (2) 2
Russian (2) 2
Turkish (2) 2
Czech (1) 1
Danish (1) 1
Dutch (1) 1
Hebrew (1) 1
Italian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Medical Clinics of North America, ISSN 0025-7125, 07/2010, Volume 94, Issue 4, pp. 743 - 759
Drug-induced hypersensitivity syndrome (DIHS) is a severe systemic reaction with several herpesvirus reactivations. Multiple organ failures appear during the... 
Thyroiditis | Drug-induced hypersensitivity syndrome | Hepatitis | Systemic lupus erythematosus | Limbic encephalitis | Renal dysfunction | Sclerodermoid lesion | Type 1 diabetes mellitus | INDUCED PSEUDOLYMPHOMA | LIVER-TRANSPLANTATION | TYPE-1 DIABETES-MELLITUS | HEMOPHAGOCYTIC SYNDROME | HUMAN-HERPESVIRUS 6 | HUMAN-HERPESVIRUS-6 REACTIVATION | VERSUS-HOST-DISEASE | SYSTEMIC SYMPTOMS | INDUCED DRESS SYNDROME | MEDICINE, GENERAL & INTERNAL | Lung Diseases - chemically induced | Multiple Organ Failure - virology | Multiple Organ Failure - chemically induced | Risk Factors | Herpesviridae Infections - chemically induced | Herpesviridae Infections - virology | Meningoencephalitis - chemically induced | Syndrome | Chemical and Drug Induced Liver Injury - diagnosis | Scleroderma, Systemic - chemically induced | Digestive System Diseases - chemically induced | Time Factors | Herpesviridae - physiology | Diabetes Mellitus, Type 1 - chemically induced | Kidney Diseases - chemically induced | Drug Hypersensitivity - diagnosis | Digestive System Diseases - etiology | Lupus Erythematosus, Systemic - chemically induced | Autoimmune Diseases - chemically induced | Drug Hypersensitivity - complications | Heart Diseases - chemically induced | Virus Activation | Chemical and Drug Induced Liver Injury - etiology | Thyroiditis - chemically induced
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2016, Volume 44, pp. 51 - 60
Highlights • Role of immune checkpoint inhibition in the management of key malignancies. • Description of rates of immune-related adverse events and timing of... 
Hematology, Oncology and Palliative Medicine | Pembrolizumab | Immune-related adverse events | Renal cancer | Ipilimumab | Nivolumab | Lung cancer | Melanoma | Immune-checkpoint inhibitors | OPEN-LABEL | SINGLE-ARM | ANTI-CTLA-4 ANTIBODY | METASTATIC MELANOMA | ONCOLOGY | ADVANCED MELANOMA | LONG-TERM SAFETY | MALIGNANT MESOTHELIOMA | ENTERIC NEUROPATHY | ADVERSE EVENTS | IPILIMUMAB RETREATMENT | Lung Neoplasms - drug therapy | Skin Neoplasms - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Adrenal Cortex Hormones - therapeutic use | Diarrhea - chemically induced | Infliximab - therapeutic use | Drug Eruptions - drug therapy | Antineoplastic Agents - adverse effects | Colitis - chemically induced | Antilymphocyte Serum - therapeutic use | Colitis - drug therapy | Carcinoma, Renal Cell - drug therapy | Chemical and Drug Induced Liver Injury - etiology | Pituitary Diseases - chemically induced | Pituitary Diseases - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Drug Eruptions - etiology | Neoplasms - drug therapy | Cyclosporine - therapeutic use | Tacrolimus - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Melanoma - drug therapy | Chemical and Drug Induced Liver Injury - drug therapy | Diarrhea - drug therapy | CTLA-4 Antigen - antagonists & inhibitors | Kidney Neoplasms - drug therapy | Thyroiditis - drug therapy | Thyroiditis - chemically induced | Index Medicus
Journal Article
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 08/2017, Volume 102, Issue 8, pp. 2770 - 2780
Context: Thyroid immune-related adverse events (irAEs) in patients treated with programmed death receptor-1 (PD-1) blockade are increasingly recognized as one... 
CELL LUNG-CANCER | UNTREATED MELANOMA | IMMUNE CHECKPOINT INHIBITORS | ADVANCED MELANOMA | AUTOIMMUNE-DISEASES | PD-1 BLOCKADE | ENDOCRINOLOGY & METABOLISM | GRAVES-DISEASE | NIVOLUMAB PLUS IPILIMUMAB | ADVERSE EVENTS | F-18-FDG UPTAKE | Hypothyroidism - chemically induced | Hypothyroidism - metabolism | Lung Neoplasms - drug therapy | Thyroid Function Tests | Humans | Middle Aged | Male | Monocytes - immunology | Positron-Emission Tomography | Hypothyroidism - diagnostic imaging | Young Adult | Triiodothyronine - metabolism | Antineoplastic Agents - adverse effects | Aged, 80 and over | Killer Cells, Natural - immunology | Thyroiditis - immunology | Adult | Female | Retrospective Studies | Thyroxine - therapeutic use | Radiopharmaceuticals | Thyroiditis - diagnostic imaging | Antibodies, Monoclonal, Humanized - adverse effects | Iodide Peroxidase - immunology | Thyroiditis - metabolism | Iron-Binding Proteins - immunology | Immunoglobulins, Thyroid-Stimulating - immunology | Thyrotropin - metabolism | Autoantibodies - immunology | Melanoma - secretion | Autoantigens - immunology | Melanoma - drug therapy | Thyroxine - metabolism | Hypothyroidism - drug therapy | Fluorodeoxyglucose F18 | Aged | HLA-DR Antigens - immunology | Carcinoma, Non-Small-Cell Lung - drug therapy | Cohort Studies | Thyroiditis - chemically induced | Flow cytometry | PD-1 protein | Antibodies | Thyroid gland | Lymphocytes T | Males | CD14 antigen | Infusion | Pathways | Thyroxine | Peripheral blood | Natural killer cells | CD56 antigen | Thyroid | Thyroiditis | Autoantibodies | Iodide peroxidase | Inflammation | Hypothyroidism | Patients | Cytometry | Monocytes | CD16 antigen | Thyroid cancer | Histocompatibility antigen HLA | Cancer | Apoptosis
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2009, Volume 63, Issue 2, pp. 219 - 227
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 11/2017, Volume 66, Issue 11, pp. 1399 - 1410
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2006, Volume 354, Issue 26, pp. 2783 - 2793
Journal Article